Hepatitis C: latest news

Hepatitis C resources

Hepatitis C features

Hepatitis C in your own words

Hepatitis C news from aidsmap

More news

Hepatitis C news selected from other sources

  • New HCV drugs pass muster in real world

    Clinical trials for some of the new direct-acting agents against hepatitis C (HCV) have yielded some impressive efficacy numbers. But how well do the drugs stack up in the real world?

    11 November 2014 | MedPage Today
  • New pill that can cure hepatitis C approved for patients in Scotland

    Daclatasvir is an oral once-daily pill, used in combination with other medicinal products, to treat adult patients with chronic hepatitis C. The decision makes Scotland the first country in Europe to adopt positive guidance for daclatasvir and means it will be routinely available to eligible patients through the Scottish NHS.

    11 November 2014 | STV
  • Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

    “Unfortunately, history seems to be repeating itself with BMS, who hasn’t learned from the company’s poor track record responding to the HIV epidemic,” says Rohit Malpani of Doctors Without Borders.

    05 November 2014 | Wall Street Journal
  • Half of people with hepatitis C unaware

    Dr Vivian Hope of Public Health England said: "With around half of those people living with hepatitis C still unaware of their infection, we need to do more to increase diagnosis rates. Ultimately, this will help reduce the current high level of infection we’re still seeing among people who inject drugs."

    05 November 2014 | Public Health England press release
  • IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

    AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

    16 October 2014 | HIVandHepatitis.com
  • Investigating an outbreak of hepatitis C virus among MSM without HIV

    Given the reports about the high-risk practices taking place in London (and likely other cities in high-income countries), it is likely that cases of sexually transmitted HCV are also occurring in some HIV-negative MSM. To investigate this possibility, researchers in London reviewed health-related information collected from HIV-negative patients who sought care at selected clinics in that city.

    01 October 2014 | CATIE
  • Uncovering cases of early HCV infection in HIV-positive men

    While screening the blood samples of patients for HCV antibodies can be useful, a new study suggests that in some cases such antibodies may not appear for several months after HCV infection has occurred. In such cases, acute HCV infection might be missed if antibody tests alone are used for screening - RNA testing should be used to screen HCV infection.

    17 September 2014 | CATIE
  • European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

    Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daklinza, when used in combination with sofosbuvir (Sovaldi), is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials

    27 August 2014 | Bristol-Myers Squibb
  • In patients co-infected with HIV, combination antiretroviral therapy helps treat HCV

    Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published in Science Translational Medicine.

    25 July 2014 | HIV / AIDS News From Medical News Today
  • US: Studies look at hepatitis C care cascade and healthcare utilization

    Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE.

    08 July 2014 | HIVandHepatitis.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.